for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cue Biopharma Inc

CUE.OQ

Latest Trade

7.12USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.16

 - 

9.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.12
Open
--
Volume
--
3M AVG Volume
1.68
Today's High
--
Today's Low
--
52 Week High
9.90
52 Week Low
4.16
Shares Out (MIL)
22.58
Market Cap (MIL)
160.79
Forward P/E
-3.63
Dividend (Yield %)
--

Latest Developments

More

Cue Biopharma Promotes Dr. Anish Suri To President And CSO

Cue Biopharma Announces FDA Acceptance Of Ind For Lead Immuno-Oncology Candidate, Cue-101, In Treatment Of Hpv-Driven Cancers

Cue Biopharma - On April 30,Gary Schuman Resigned As Interim CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cue Biopharma Inc

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Industry

Biotechnology & Drugs

Contact Info

21 Erie St

+1.617.9492680

https://www.cuebiopharma.com/

Executive Leadership

Barry J. Simon

Independent Chairman of the Board

Anish Suri

President, Chief Scientific Officer

Daniel R. Passeri

Chief Executive Officer, Director

Rodolfo J. Chaparro

Executive Vice President - Head of Immunology

Ronald D. Seidel

Executive Vice President - Head of Research and Development

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-1.940

2019(E)

-1.960
Price To Earnings (TTM)
--
Price To Sales (TTM)
72.93
Price To Book (MRQ)
7.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-112.82
Return on Equity (TTM)
-94.80

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up